The FDA line, in plain English.

The gate, in one diagram

The FDA's framework, codified at 21 CFR 1271.10 is structured as a gate. Every cell preparation a U.S. clinic offers either passes through it or doesn't. There is no middle tier, no "lightly regulated as a drug" category. You are either a tissue (§361) or a biologic drug (§351). The gate decides which.

Every clinic in the United States offering "stem cell therapy" is, whether they say so or not, operating their entire program around staying on the left side of this gate. The cells they offer, the volumes they draw, the same-day workflow, the language on their website, the indications they will treat, all of it is shaped by the four prongs above.

The next four sections walk through each prong, what it actually means, and the specific clinic practices it forces.

The first prong asks whether the processing alters the tissue's "original relevant characteristics". Translating: the cells you put in have to be doing the same thing, structurally and biologically, as the cells that came out. Wash them. Spin them. Filter them. Freeze them. Fine. The moment you culture them, give them food and time to multiply, you have manipulated them more than minimally, and the gate closes.

This is the prong that forces the most visible practice in U.S. stem-cell medicine: same-day, in-clinic procedures. If the cells leave the body, get cultured for two weeks, and come back as a billion-cell infusion, they're a drug. So the cells never leave. They go from your hip to a benchtop centrifuge to a syringe to your knee, all in 90 minutes. That entire workflow exists because of one phrase in one subsection of the Code of Federal Regulations.

The second prong asks a question that feels intuitive once you see it: are the cells doing the same job in the new location as they did in the old one? Bone marrow used to repair bone: homologous. Skin used to repair skin: homologous. Fat-derived cells injected into a knee to "regenerate cartilage": not homologous, because fat tissue's job in the body is not cartilage maintenance.

This is the prong most U.S. wellness clinics quietly fail in their marketing. The treatment itself might be a §361-defensible adipose SVF preparation. But the page that says "stem cells for autoimmune disease, neurodegenerative conditions, and anti-aging" describes a use that is, by FDA's reading, non-homologous. and therefore a drug. The cells didn't change. The intent changed.

The third prong is narrower than the first two, but it has real teeth. If a clinic mixes the cells with a pharmaceutical compound: say, a growth factor, a steroid, a synthetic scaffold material, an exosome cocktail from a different source, the resulting product is generally no longer a §361 tissue. It has become a combination product, evaluated as a drug.

The third prong is where a lot of "advanced" or "premium" U.S. offerings quietly cross into drug territory. A clinic offering "stem cells with exosomes and growth factor matrix" is, regardless of marketing language, describing a combination product. The product as a whole is what FDA evaluates, not just the cell fraction.

The fourth prong is the most technical, and most clinics talk around it. It splits into two halves. (i) If the cell preparation does not depend on the metabolic activity of living cells for its primary function, and does not act systemically, it's fine, no further test. (ii) If it does depend on living cells, or does act systemically, then it has to be either autologous (the patient's own cells) or from a first/second-degree blood relative, or for reproductive use.

The fourth prong is what makes "allogeneic IV stem cells" the offering most patients researching this space are actually looking for, categorically a §351 drug in the United States, requiring an active IND. There is no §361 path to systemic donor cells.

Reading clinic marketing through the four prongs.

Most prospective patients never read the CFR. They read clinic websites. Once you know the four prongs, every familiar phrase in U.S. stem-cell marketing maps to one of them, usually as a careful sidestep around a prong the clinic does not want to fail.

The four prongs are an FDA story. The FTC has its own.

The FDA decides whether the product is legal to sell. The Federal Trade Commission decides whether the advertising that sells it is honest. These are two different statutes, two different agencies, and two different standards of proof. A U.S. clinic can satisfy one and be crosswise with the other.

FDA jurisdiction: the product.

Statute is the Federal Food, Drug, and Cosmetic Act. Tools are warning letters, seizures, injunctions, criminal referral. Remedy targets the manufacture and the path to market. The four prongs above are the test.

FTC jurisdiction: the advertising.

Statute is Section 5 of the FTC Act, with Section 12 covering false advertising of drugs, devices, and services specifically. The threshold for every health claim is "competent and reliable scientific evidence" for the specific indication and the specific product. Tools are consent orders, civil penalties, monetary refunds, and permanent bans on the people who signed off on the ads.

The largest stem-cell advertising enforcement in U.S. history is FTC, not FDA.

In December 2024, a federal court in Georgia entered a $5.15 million judgment against the founders of Stem Cell Institute of America and Superior Healthcare, and permanently banned them from advertising, marketing, promoting, or selling any regenerative-medicine treatment that meets the definition of stem-cell therapy. The product was not novel. The marketing was.

For a reader of U.S. clinic websites the practical implication is straightforward. An FDA warning letter is about what is in the syringe. An FTC consent order is about what is on the page. A clinic can revise the preparation to satisfy the FDA and keep getting sued by the FTC because the marketing keeps over-promising. The phrase "FDA-regulated" on a clinic page, written to imply that the agency has cleared something it has not, is the kind of sentence that triggers both.